| 摘要 |
This invention provides stable, sterile, ready-to-use formulations of oncolytic vinca dimers comprising an aqueous solution of the vinca dimer (e.g. vincristine, vinblastine, vindesine, 4 min -deoxy-1-formyl-leurosidine or leuraformine) as a pharmaceutically acceptable water-soluble salt, an acetate buffer maintaining the pH between 3.0 and 5.0, a polyol (e.g. lactose, mannitol, sorbitol), and a preservative which is preferably methyl paraben and/or propyl paraben. |
